Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases

BACKGROUND & AIMS: There are few real-world data on the safety of vedolizumab for treatment of Crohn’s disease (CD) or ulcerative colitis (UC). We quantified rates and identified factors significantly associated with infectious and non-infectious adverse events in clinical practice. METHODS: We...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Gastroenterol Hepatol
Autori principali: Meserve, Joseph, Aniwan, Satimai, Koliani-Pace, Jenna L., Shashi, Preeti, Weiss, Aaron, Faleck, David, Winters, Adam, Chablaney, Shreva, Kochhar, Gursimran, Boland, Brigid S., Singh, Siddharth, Hirten, Robert, Shmidt, Eugenia, Hartke, Justin G., Chilukuri, Prianka, Bohm, Matthew, Sagi, Sashidhar Varma, Fischer, Monika, Lukin, Dana, Hudesman, David, Chang, Shannon, Gao, Youran, Sultan, Keith, Swaminath, Arun, Gupta, Nitin, Kane, Sunanda, Loftus, Edward V., Shen, Bo, Sands, Bruce E., Colombel, Jean-Frederic, Siegel, Corey A., Sandborn, William J., Dulai, Parambir S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6594363/
https://ncbi.nlm.nih.gov/pubmed/30268561
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cgh.2018.09.035
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi